Is Latuda Approved for Bipolar Depression?
Latuda (lurasidone) is FDA-approved for treating depressive episodes in adults and children aged 10+ with bipolar depression, either as monotherapy or with lithium or valproate. Clinical trials showed it reduces depressive symptoms, with response rates of 53-60% versus 30-43% for placebo.[1][2]
How Does Latuda Work for Bipolar?
It acts as an atypical antipsychotic, blocking dopamine D2 and serotonin 5-HT2A receptors while activating 5-HT1A receptors and partially blocking 5-HT7. This targets mood stabilization and depressive symptoms without strong sedation or weight gain common in other antipsychotics.[1][3]
How Effective Is It Compared to Placebo?
In two 6-week trials (n=505, n=511), Latuda at 20-120 mg/day led to Montgomery-Åsberg Depression Rating Scale (MADRS) score reductions of 15-17 points, versus 11-13 for placebo (p<0.001). Remission rates hit 44-53% on Latuda.[2][4] Long-term data (up to 24 weeks) supports sustained response in 60-70% of patients.[1]
What Dosage and Timeline for Bipolar Depression?
Start at 20 mg/day, titrate to 20-120 mg based on response and tolerability, taken with food (≥350 calories for absorption). Improvement often starts in 1-2 weeks, peaks at 6 weeks. Maintenance dosing mirrors acute.[1][5]
Common Side Effects Patients Report
Akathisia (10-22%), nausea (10-17%), somnolence (10-13%), and restlessness occur most. Less weight gain (0.1-0.4 kg average) than olanzapine or quetiapine. Rare risks include tardive dyskinesia, neuroleptic malignant syndrome, and metabolic changes; monitor lipids and glucose.[1][6] Patient forums note akathisia as a frequent reason for stopping.
How Does Latuda Compare to Other Bipolar Depression Treatments?
| Treatment | Key Differences from Latuda |
|-----------|-----------------------------|
| Quetiapine (Seroquel) | Similar efficacy; more sedation, weight gain (2-3 kg). Approved monotherapy.[4] |
| Olanzapine-fluoxetine (Symbyax) | Higher remission (50-65%); substantial weight gain (3+ kg), metabolic risks.[4] |
| Cariprazine (Vraylar) | Comparable MADRS reductions; more akathisia, less nausea.[7] |
| Lamotrigine | Better for maintenance; weaker acute depression response.[8] |
Latuda edges out on tolerability for weight-conscious patients.[4][7]
Who Should Avoid Latuda?
Contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin). Caution in elderly dementia patients (increased mortality risk), Parkinson's, or seizure history. Pregnancy: category B, limited data.[1][5]
When Does the Latuda Patent Expire?
Core patents expired in 2023, but pediatric exclusivity extends to January 2024. Generic entry began mid-2024; check DrugPatentWatch.com for latest litigation and ANDA approvals.[9]
[1]: Latuda Prescribing Information, Sunovion, 2023. https://www.latuda.com
[2]: Loebel A, et al. Lancet. 2014. PMID: 24589148
[3]: Ishibashi T, et al. J Pharmacol Exp Ther. 2010. PMID: 20679197
[4]: McIntyre RS, et al. Am J Psychiatry. 2017. PMID: 28554317
[5]: FDA Label, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/200603s037lbl.pdf
[6]: Citrome L. Int J Clin Pract. 2013. PMID: 23683048
[7]: Earley W, et al. Am J Psychiatry. 2019. PMID: 30895819
[8]: Goodwin GM, et al. Lancet. 2004. PMID: 15364185
[9]: DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/LATUDA